New York and Denver-based Y-mAbs Therapeutics, a developer of cancer treatments, has raised $96 million for its IPO after pricing its 6 million shares at $16 per share. The stock began trading September 21, 2018 on the NASDAQ under the ticker symbol “YMAB.” BofA Merrill Lynch and Cowen are the lead underwriers. Y-mAbs Therapeutics Inc’ pre-IPO investors included Sofinnova Ventures and Scopia Capital Management.
NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $96 million, before underwriting discounts and commissions and estimated offering expenses payable by the Company. All shares are being offered by the Company.
In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock from the Company at the initial public offering price, less underwriting discounts and commissions.
The Company’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “YMAB” on Friday, September 21, 2018. The offering is expected to close on Tuesday, September 25, 2018, subject to customary closing conditions.
BofA Merrill Lynch and Cowen are acting as joint book-running managers for the offering. Canaccord Genuity is acting as lead manager for the offering and BTIG is acting as co-manager for the offering.
A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission (the “SEC”) on September 20, 2018. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus Department or by email at firstname.lastname@example.org; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by phone at (631) 274-2806.
Additionally, when available, copies of these documents may be obtained for free by accessing the EDGAR database on the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates, naxitamab and omburtamab, which target tumors that express GD2 and B7-H3, respectively.